[ Swiss Bridge Foundation - Swiss Bridge Award 2019 | Research funding ]

Swiss Bridge is a private foundation associated with the Swiss Cancer League, the Swiss Cancer Research foundation and the Union for International Cancer Control, which supports high-quality cancer research in Europe.
 
The 2019 call focuses on immune cell therapy, including all types of immune-cell therapies, such as chimeric antigen receptor T-cell (CAR T-cell) therapy, tumor-infiltrating lymphocytes (TILs) therapy, and dendritic cell vaccine therapy.
 
Who can apply: early stage researchers (under the age of 45) holding a PhD or MD and having obtained an independent position at a hospital, university, or research institute in Europe (e.g. junior group leaders, assistant professors, lecturers, scientists establishing their own research group).
 
Funding & duration: max. CHF 300’000 for up to 36 months.

• Covers: personnel (excluding the PI’s salary), consumables, travel cost, publications fees.
• Does NOT cover: indirect costs, infrastructure, bench fees and overheads.

• Internal deadline for Institutional Support Letter: 22 April 2019 (contact [email protected]).
• Deadline for Letter of Intent: 30 April 2019 (submit single PDF to [email protected]).
• The Letter of Intent (max. 6 pages) will be evaluated by an international scientific jury.
• 6-8 investigators will be shortlisted and invited to submit a detailed research application.
• Full proposal: .
• Upon peer review and recommendation from the scientific jury, up to 3 projects will receive funding.